Retatrutide: The "Triple G" Agonist
An investigational molecule targeting three distinct hormone receptors to achieve metabolic effects surpassing current therapies. Developed by Eli Lilly, it represents the next generation of obesity and diabetes treatment.
Why is this significant?
Current market leaders like Semaglutide (Wegovy) and Tirzepatide (Zepbound) target one or two receptors, respectively. Retatrutide adds a third target—glucagon—which historically was thought to raise blood sugar. However, in this specific triple-combination, glucagon appears to increase energy expenditure (burning calories) and rapidly clear liver fat, while the other two hormones maintain insulin secretion and suppress appetite.
Key Takeaway Early data suggests efficacy approaching that of bariatric surgery, with a safety profile generally consistent with existing incretin-based therapies.